Literature DB >> 17542011

Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Murat Emre1, Dag Aarsland, Richard Brown, David J Burn, Charles Duyckaerts, Yoshikino Mizuno, Gerald Anthony Broe, Jeffrey Cummings, Dennis W Dickson, Serge Gauthier, Jennifer Goldman, Christopher Goetz, Amos Korczyn, Andrew Lees, Richard Levy, Irene Litvan, Ian McKeith, Warren Olanow, Werner Poewe, Niall Quinn, Christina Sampaio, Eduardo Tolosa, Bruno Dubois.   

Abstract

Dementia has been increasingly more recognized to be a common feature in patients with Parkinson's disease (PD), especially in old age. Specific criteria for the clinical diagnosis of dementia associated with PD (PD-D), however, have been lacking. A Task Force, organized by the Movement Disorder Study, was charged with the development of clinical diagnostic criteria for PD-D. The Task Force members were assigned to sub-committees and performed a systematic review of the literature, based on pre-defined selection criteria, in order to identify the epidemiological, clinical, auxillary, and pathological features of PD-D. Clinical diagnostic criteria were then developed based on these findings and group consensus. The incidence of dementia in PD is increased up to six times, point-prevelance is close to 30%, older age and akinetic-rigid form are associated with higher risk. PD-D is characterized by impairment in attention, memory, executive and visuo-spatial functions, behavioral symptoms such as affective changes, hallucinations, and apathy are frequent. There are no specific ancillary investigations for the diagnosis; the main pathological correlate is Lewy body-type degeneration in cerebral cortex and limbic structures. Based on the characteristic features associated with this condition, clinical diagnostic criteria for probable and possible PD-D are proposed. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17542011     DOI: 10.1002/mds.21507

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  794 in total

1.  Amyloid imaging of Lewy body-associated disorders.

Authors:  Erin R Foster; Meghan C Campbell; Michelle A Burack; Johanna Hartlein; Hubert P Flores; Nigel J Cairns; Tamara Hershey; Joel S Perlmutter
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  Neuropsychology, neuroimaging or motor phenotype in diagnosis of Parkinson's disease-dementia: which matters most?

Authors:  Francesca Di Biasio; Nicola Vanacore; Alfonso Fasano; Nicola Modugno; Barbara Gandolfi; Francesco Lena; Giovanni Grillea; Sara Pietracupa; Giovanni Caranci; Stefano Ruggieri
Journal:  J Neural Transm (Vienna)       Date:  2011-12-13       Impact factor: 3.575

Review 3.  Evolution of the diagnostic criteria for degenerative and cognitive disorders.

Authors:  Oscar L Lopez; Eric McDade; Mario Riverol; James T Becker
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

Review 4.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

5.  Sentence processing in Lewy body spectrum disorder: the role of working memory.

Authors:  Rachel G Gross; Corey T McMillan; Keerthi Chandrasekaran; Michael Dreyfuss; Sharon Ash; Brian Avants; Philip Cook; Peachie Moore; David J Libon; Andrew Siderowf; Murray Grossman
Journal:  Brain Cogn       Date:  2012-01-02       Impact factor: 2.310

Review 6.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Authors:  Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre
Journal:  Mov Disord       Date:  2012-01-24       Impact factor: 10.338

7.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

8.  Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.

Authors:  Sarra Nazem; Andrew D Siderowf; John E Duda; Tom Ten Have; Amy Colcher; Stacy S Horn; Paul J Moberg; Jayne R Wilkinson; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  J Am Geriatr Soc       Date:  2008-12-10       Impact factor: 5.562

Review 9.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 10.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.